Our current study confirmed the expression of EZHIP in NSCLC on the protein level, and the association with plasma cell infiltration (mainly in SCC histology) strengthens the supposition that EZHIP is a CTA candidate with therapeutic potential. The gene discussed is EZHIP; the disease is non-small cell lung carcinoma.